Compare DexCom, Inc. (DXCM) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Nano Dimension Ltd - ADR — how do they compare? DexCom, Inc. trades at $90.63 (market cap $33.79B), while Nano Dimension Ltd - ADR trades at $1.65 (market cap $350.49M). The key difference: DexCom, Inc. is far larger — about 96.4× Nano Dimension Ltd - ADR's market cap, and DexCom, Inc. is trading nearer its 52-week high, Nano Dimension Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| DXCM | NNDM | |
|---|---|---|
Market Cap | $33.79B | $350.49M |
Sector | Health | Technology |
52-Week High | $89.53 | $2.14 |
52-Week Low | $54.84 | $1.21 |
Enterprise Value | $33.24B | -$54.35M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
NNDM trades at $1.655, up 1.53% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q2 2026 EPS of -$0.03, beating expectations, while revenue grew to $102.44M in 2025. However, net income remains deeply negative at -$293.30M, and cash flow from operations is negative. Recent strategic moves include selling MarkForged to Stratasys and cost-saving initiatives to reduce cash burn.
Outlook: Potential upside from strategic divestitures and cost cuts, but high execution risk and persistent losses pose significant challenges. Investors should weigh the low P/B of 0.73 against sustained profitability concerns and shareholder disputes highlighted in recent news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
